Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Mallinckrodt
Colorcon
Fish and Richardson
Julphar
McKesson
QuintilesIMS
UBS
Deloitte
Argus Health

Generated: February 19, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,807,689

« Back to Dashboard

Which drugs does patent 7,807,689 protect, and when does it expire?

Patent 7,807,689 protects KAZANO, NESINA, and OSENI, and is included in three NDAs.

This patent has fifty patent family members in thirty-one countries.
Summary for Patent: 7,807,689
Title:Dipeptidyl peptidase inhibitors
Abstract: The present invention provides a compound of the formula: ##STR00001## or stereoisomers or pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, articles of manufacture comprising the same, and methods of using the same.
Inventor(s): Zhang; Zhiyuan (San Diego, CA), Elder; Bruce J. (Wynantskill, NY), Isbester; Paul K. (Castleton, NY), Palmer; Grant J. (Clifton Park, NY), Ulysse; Luckner G. (Albany, NY)
Assignee: Takeda Pharmaceutical Company Limited (Osaka, JP)
Application Number:11/080,992
Patent Claim Types:
see list of patent claims
Compound; Composition; Formulation; Dosage form; Delivery; Use;

Drugs Protected by US Patent 7,807,689

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Takeda Pharms Usa KAZANO alogliptin benzoate; metformin hydrochloride TABLET;ORAL 203414-002 Jan 25, 2013 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN ➤ Sign Up
Takeda Pharms Usa KAZANO alogliptin benzoate; metformin hydrochloride TABLET;ORAL 203414-001 Jan 25, 2013 RX Yes No ➤ Sign Up ➤ Sign Up Y Y METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN ➤ Sign Up
Takeda Pharms Usa NESINA alogliptin benzoate TABLET;ORAL 022271-001 Jan 25, 2013 RX Yes No ➤ Sign Up ➤ Sign Up Y Y METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN ➤ Sign Up
Takeda Pharms Usa NESINA alogliptin benzoate TABLET;ORAL 022271-002 Jan 25, 2013 RX Yes No ➤ Sign Up ➤ Sign Up Y Y METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN ➤ Sign Up
Takeda Pharms Usa NESINA alogliptin benzoate TABLET;ORAL 022271-003 Jan 25, 2013 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN ➤ Sign Up
Takeda Pharms Usa OSENI alogliptin benzoate; pioglitazone hydrochloride TABLET;ORAL 022426-004 Jan 25, 2013 RX Yes No ➤ Sign Up ➤ Sign Up Y Y METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN ➤ Sign Up
Takeda Pharms Usa OSENI alogliptin benzoate; pioglitazone hydrochloride TABLET;ORAL 022426-005 Jan 25, 2013 RX Yes No ➤ Sign Up ➤ Sign Up Y Y METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN ➤ Sign Up
Takeda Pharms Usa OSENI alogliptin benzoate; pioglitazone hydrochloride TABLET;ORAL 022426-006 Jan 25, 2013 RX Yes No ➤ Sign Up ➤ Sign Up Y Y METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN ➤ Sign Up
Takeda Pharms Usa OSENI alogliptin benzoate; pioglitazone hydrochloride TABLET;ORAL 022426-001 Jan 25, 2013 RX Yes No ➤ Sign Up ➤ Sign Up Y Y METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN ➤ Sign Up
Takeda Pharms Usa OSENI alogliptin benzoate; pioglitazone hydrochloride TABLET;ORAL 022426-002 Jan 25, 2013 RX Yes No ➤ Sign Up ➤ Sign Up Y Y METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 7,807,689

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,781,584 Dipeptidyl peptidase inhibitors ➤ Sign Up
8,173,663 Dipeptidyl peptidase inhibitors ➤ Sign Up
8,188,275 Dipeptidyl peptidase inhibitors ➤ Sign Up
8,329,900 Dipeptidyl peptidase inhibitors ➤ Sign Up
8,288,539 Dipeptidyl peptidase inhibitors ➤ Sign Up
7,795,428 Dipeptidyl peptidase inhibitors ➤ Sign Up
7,906,523 Dipeptidyl peptidase inhibitors ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 7,807,689

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 048055 ➤ Sign Up
Argentina 103423 ➤ Sign Up
Austria 401320 ➤ Sign Up
Australia 2004318013 ➤ Sign Up
Brazil PI0418639 ➤ Sign Up
Canada 2559302 ➤ Sign Up
China 102079743 ➤ Sign Up
China 102127053 ➤ Sign Up
China 102127057 ➤ Sign Up
China 102134229 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Teva
Queensland Health
UBS
Julphar
Citi
AstraZeneca
Express Scripts
Merck
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot